SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma reports 17% rise in Q4 consolidated net profit

20 May 2025 Evaluate

Marksans Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported 13.94% rise in its net profit at Rs 37.59 crore for the quarter under review as compared to Rs 32.99 crore for the same quarter in the previous year. The total income of the company increased by 29.39% at Rs 307.17 crore for Q4FY25 as compared to Rs 237.39 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 16.86% rise in its net profit at Rs 90.73 crore for fourth quarter ended March 31, 2025 as compared to Rs 77.64 crore for the same quarter in the previous year. The total income of the company increased by 25.75% at Rs 724.98 crore for Q4FY25 as compared to Rs 576.54 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported 40.75% rise in its net profit at Rs 188.27 crore as compared to Rs 133.76 crore for the previous year. The total income of the company increased by 35.93% at Rs 1,244.21 crore for year under review as compared to Rs 915.35 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported 21.51% rise in its net profit at Rs 382.62 crore as compared to Rs 314.90 crore for the previous year. The total income of the company increased by 20.89% at Rs 2,693.22 crore for year under review as compared to Rs 2,227.83 crore for year ended March 31, 2024.

Marksans Pharma Share Price

180.50 1.60 (0.89%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×